Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review

PMID: 25259676
Journal: Cancer investigation (volume: 32, issue: 9, Cancer Invest. 2014 Nov;32(9):451-7)
Published: 2014-09-26

Authors:
Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB

ABSTRACT

OBJECTIVE: Glioblastoma multiforme (GBM) has a poor prognosis. The purpose of this systematic review and meta-analysis was to analyze the outcomes of clinical trials which compared immunotherapy with conventional therapy for the treatment of malignant gliomas.

METHODS: PubMed, Cochrane and Google Scholar databases were searched for relevant studies. The 2-year survival rate was used to evaluate effectiveness of immunotherapy.

RESULTS: Of 171 studies identified, six comparative trials were included in the systematic review. Immunotherapy was associated with a significantly longer OS and 2-year survival compared to conventional therapy.

CONCLUSION: Immunotherapy may improve the survival of patients with GBM.